Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 1, 2024

Consolidated Financial Summary for the First Three Months of the Fiscal Year Ending March 31, 2025 (Under Japanese GAAP)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: Tokyo Stock Exchange)
Code Number: 4559 (URL: https://www.zeria.co.jp/english/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Tomoyuki Nishizawa, Director, Public Relations Division TEL (03) 3661-1039
Scheduled date to commence dividend payments: –
Preparation of supplementary documents to the financial results: None
Holding of financial results presentation: None

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2024 through June 30, 2024)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
June 30, 2024	21,455	17.2	3,939	32.6	5,459	62.7	4,212	44.5
June 30, 2023	18,304	12.3	2,970	(0.2)	3,355	12.8	2,915	12.1

Note: Comprehensive income: For the three months ended June 30, 2024: 3,318 million yen [26.5%]
For the three months ended June 30, 2023: 2,622 million yen [(19.6)%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2024	95.57	–
June 30, 2023	66.14	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
June 30, 2024	152,115	82,177	53.9
March 31, 2024	150,533	79,828	52.9

Reference: Equity: As of June 30, 2024: 81,931 million yen As of March 31, 2024: 79,622 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2024	–	22.00	–	22.00	44.00
Year ending March 31, 2025	–				
Year ending March 31, 2025 (Forecast)		23.00	–	23.00	46.00

Note: Revision of the forecast of dividends most recently announced: None

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2025 (April 1, 2024 through March 31, 2025)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
First six months	41,000	11.8	5,600	5.1	5,600	1.9	4,300	(20.3)	97.55
Full year	83,000	9.6	10,000	3.9	10,000	17.5	7,800	0.9	176.95

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None
Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections
1) Changes in accounting policies due to revisions to accounting standards and other regulations: Yes
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: None
4) Restatement of prior period financial statements after error corrections: None

(4) Number of shares issued (common shares)
1) Number of shares issued as of the end of the term (including treasury shares):
As of June 30, 2024: 53,119,190 shares As of March 31, 2024: 53,119,190 shares
2) Number of shares of treasury shares as of the end of the term:
As of June 30, 2024: 9,039,525 shares As of March 31, 2024: 9,039,354 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the three months ended June 30, 2024: 44,079,743 shares
For the three months ended June 30, 2023: 44,080,208 shares

* Review of the Japanese-language originals of the attached quarterly consolidated financial statements by certified public accountants or an audit corporation: None

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors.